JNJ-88549968

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-88549968, covering 2026-04-14 to 2026-04-14. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms [Phase 1]